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Prognostic impact of elevated lactate 
levels on mortality in critically ill patients 
with and without preadmission metformin 
treatment: a Danish registry-based cohort study
Rene A. Posma1,2* , Trine Frøslev2, Bente Jespersen3 , Iwan C. C. van der Horst4 , Daan J. Touw5 , 
Reimar W. Thomsen2 , Maarten W. Nijsten1  and Christian F. Christiansen2 
Abstract 
Background: Lactate is a robust prognostic marker for the outcome of critically ill patients. Several small studies 
reported that metformin users have higher lactate levels at ICU admission without a concomitant increase in mor-
tality. However, this has not been investigated in a larger cohort. We aimed to determine whether the association 
between lactate levels around ICU admission and mortality is different in metformin users compared to metformin 
nonusers.
Methods: This cohort study included patients admitted to ICUs in northern Denmark between January 2010 and 
August 2017 with any circulating lactate measured around ICU admission, which was defined as 12 h before until 
6 h after admission. The association between the mean of the lactate levels measured during this period and 30-day 
mortality was determined for metformin users and nonusers by modelling restricted cubic splines obtained from a 
Cox regression model.
Results: Of 37,293 included patients, 3183 (9%) used metformin. The median (interquartile range) lactate level was 
1.8 (1.2–3.2) in metformin users and 1.6 (1.0–2.7) mmol/L in metformin nonusers. Lactate levels were strongly associ-
ated with mortality for both metformin users and nonusers. However, the association of lactate with mortality was 
different for metformin users, with a lower mortality rate in metformin users than in nonusers when admitted with 
similar lactate levels. This was observed over the whole range of lactate levels, and consequently, the relation of lac-
tate with mortality was shifted rightwards for metformin users.
Conclusion: In this large observational cohort of critically ill patients, early lactate levels were strongly associated 
with mortality. Irrespective of the degree of hyperlactataemia, similar lactate levels were associated with a lower 
mortality rate in metformin users compared with metformin nonusers. Therefore, lactate levels around ICU admission 
should be interpreted according to metformin use.
Keywords: Metformin, Lactate, Effect modification, Metabolism, Diabetes mellitus
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the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
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Background
Lactate is the most robust early routine laboratory 
marker for outcome in critically ill patients [1, 2]. Lactate 
levels are generally elevated as part of the stress response 
or due to impaired lactate utilisation [3]. Therefore, 
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lactate is increasingly measured to stratify risk and to 
monitor the course of critical illness [3].
Metformin is the recommended first-line glucose-low-
ering medication for the management of type 2 diabetes 
mellitus [4]. Although its mechanism of action remains 
debated [5], metformin has been shown to selectively 
reduce hepatic lactate uptake and subsequent glucose 
production through mild inhibition of mitochondria [6–
9]. Conversion of lactate into glucose in the liver, as part 
of the Cori cycle, plays a pivotal role in lactate metabo-
lism during physiological stress [3, 10]. Inhibition of this 
cycle by metformin may result in more marked hyper-
lactataemia in times of critical illness [11]. On the other 
hand, some patients with renal dysfunction accumulate 
metformin and develop severe lactic acidosis, which is 
caused by excessive systemic and hepatic mitochondrial 
inhibition [11, 12].
Given its mechanism of action, metformin may con-
tribute to plasma lactate elevation without the patient 
being more severely ill than individuals with similar lac-
tate levels [13]. Compared to critically ill patients not 
using metformin, some studies reported that metformin 
users have higher lactate levels at admission without a 
concomitant increase in mortality [14–17], although 
others could not corroborate these findings [18–22]. To 
determine whether the association between early lactate 
level and mortality during critical illness is different in 
metformin users compared with metformin nonusers, we 
studied a large cohort of patients admitted to intensive 
care units (ICU) in northern Denmark.
Methods
Setting and inclusion
Data were collected through the unambiguous individ-
ual-level linkage between population-based medical reg-
istries and databases using the unique central personal 
identification number assigned to each Danish resident 
at birth or upon immigration [23]. We included sub-
jects aged 18 years and older who, between January 1st, 
2010 and July 31st, 2017, had a hospitalisation in north-
ern Denmark (i.e., the Northern and Central Denmark 
Regions, Additional file  1: Appendix S1) that included 
admission to the ICU. Patients were subsequently identi-
fied from the previously validated Danish Intensive Care 
Database (DID) [24], which covers virtually all patients 
admitted to an ICU in Denmark [25]. During the study 
period, all 10 hospitals in northern Denmark were con-
nected to the population-based regional laboratory 
research database, which covers both in- and outpatient 
measurements [26]. To ensure the availability of a com-
plete history of laboratory data, we required that the 
included patients lived in the area for at least 1 year [27]. 
Of patients fulfilling the criteria above, we then included 
the first ICU admission of patients with at least one 
reported blood lactate level between 12  h before until 
6 h after ICU admission. This time frame was chosen to 
capture lactate levels that are typically taken into consid-
eration to assess disease severity and monitor initiated 
treatment [28, 29]. Of patients without a lactate measure-
ment, we recorded data regarding the first ICU admis-
sion within the inclusion period. To avoid immortal time 
bias, we excluded patients who died within 6 h after ICU 
admission [30].
Preadmission metformin use
Prescription data were obtained from the nationwide 
Danish National Health Service Prescription Database 
[31]. For each patient, we identified all filled prescrip-
tions for antihyperglycemic drugs (Additional file  1: 
Appendix S2) [27, 31]. Metformin users were defined as 
patients with at least one prescription for metformin as 
monotherapy or in combination with any other antihy-
perglycemic drug within 90 days before ICU admission. 
This period was chosen because prescriptions rarely are 
issued for more than 3 months [27].
Exposure and outcome
The exposure was the mean of all lactate measurements 
obtained 12 h before until 6 h after ICU admission (Addi-
tional file  1: Fig. S1). The outcome was death within 
30  days following ICU admission. Data for all Danish 
inhabitants regarding vital status, emigration, and resi-
dency were obtained from the Danish Civil Registration 
System (DCRS) [23]. Patients were censored at the date 
of emigration or at the end of follow-up, whichever came 
first. We investigated whether metformin use interacted 
with the relation between lactate and mortality (i.e., the 
effect measure modification) [32].
Patient characteristics
We used the DCRS to obtain data on age and sex. 
Comorbidity level, according to the Charlson Comor-
bidity Index, was estimated using inpatient and outpa-
tient hospital contacts recorded in the Danish National 
Patient Registry (DNPR) within 10  years before ICU 
admission [33]. The primary diagnosis of hospitalisa-
tion in which the index ICU admission occurred, and the 
type of admission was obtained similarly from the DNPR 
[34]. Treatment initiated during ICU admission and the 
Simplified Acute Physiology Score (SAPS) II score was 
retrieved from the DID [25, 35]. We identified diabetes 
mellitus using an algorithm incorporating any previ-
ous inpatient or outpatient clinical diagnosis of diabetes 
10  years before ICU admission, any prescription for an 
oral antihyperglycemic drug or insulin 90  days before 
ICU admission, or a glycosylated haemoglobin A1c 
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(HbA1c) level ≥ 6.5% (48 mmol/mol) within a year before 
admission [27, 36]. Preadmission renal function was 
determined by calculating the mean plasma creatinine 
concentration 365  days until 7  days before ICU admis-
sion [37]. The estimated glomerular filtration rate (eGFR) 
was calculated using the Chronic Kidney Disease Epi-
demiology Collaboration equation assuming Caucasian 
race [38, 39]. Data on chronic renal replacement therapy 
(RRT) use the year before ICU admission were obtained 
from the DNPR [34].
Statistical analyses
All missing variables, provided as footnotes in Table  1, 
were imputed via multivariate imputation by chained 
equations with 100 imputation sets, using all data pre-
sented in Table 1 and Additional file 1: Table S2 as pre-
dictors to match. Estimates were pooled according to 
Rubin’s rules [40]. Differences with 95% confidence 
interval (CI) in median lactate level between metformin 
nonusers and users were computed by bootstrapping the 
median difference with 1000 resamples [41]. Addition-
ally, we compared the proportion of metformin users and 
nonusers with a maximum lactate of ≥ 2 mmol/L, which 
is often considered as the threshold level identifying 
severe critical illness, such as septic shock [42]. Thirty-
day mortality was computed as one minus the Kaplan–
Meier survival estimate.
To assess the association of lactate with outcome, 
we computed hazard ratios (HR) with 95% CI for death 
using multivariable Cox proportional hazards regression 
analysis. This model was chosen because the hazard ratio 
approximates the rate ratio at the expected event rate in 
our study, making this estimator easier to interpret than, 
for example, odds ratios [43]. The proportional hazards 
assumption was checked graphically and found to be 
met. The model was adjusted for age, sex, preadmis-
sion plasma creatinine concentration, HbA1c level, and 
several preadmission comorbidities (Additional file  1: 
Appendix S3). Creatinine was included since decreased 
renal function may, directly and indirectly, lead to 
impaired lactate metabolism [44].
The association of lactate level as a continuous vari-
able with mortality for metformin nonusers and users 
was modelled using restricted cubic splines with four 
equally spaced knots, of which the location was based on 
quantiles. Subsequently, we categorised the lactate level, 
based on the second, third, and fourth quintiles (1.4, 2.0, 
and 3.2  mmol/L, respectively) and two custom-defined 
boundaries (5.0 and 10.0 mmol/L, respectively), into six 
groups. Lactate groups, stratified by metformin use, were 
entered into the model as a categorical variable. To quan-
tify interaction on an additive scale, we calculated the 
relative excess risk due to interaction (RERI), of which 
the 95% CI was based on the delta method [32].
To investigate whether potential bias was introduced 
by imputation, we also performed all analyses in a data-
set restricted to complete cases [40]. As HbA1c was 
only reported in 15% of the patients, the complete case 
analysis was performed without including HbA1c as 
a covariable. We also performed our primary analy-
sis in subgroups, including (1) patients with diabetes, 
(2) patients admitted for elective surgery, and (3) after 
stratification by preadmission renal function. The last 
subgroup was chosen because metformin-associated 
lactic acidosis might be more prevalent among met-
formin users with chronic kidney disease [11, 45, 46]. 
Additionally, we corrected for potential surveillance bias 
by adjusting for the number of lactate measurements in 
a separate analysis. Details regarding covariates used in 
the models for each subgroup are outlined in Additional 
file 1: Appendix S4. To further confirm the robustness of 
our findings, we performed the primary analysis using 
the first and the maximum lactate concentration as expo-
sure. We also applied a logistic regression model to deter-
mine the association of lactate level with mortality.
Data were analysed with R version 3.5.1 (R Founda-
tion for Statistical Computing, Vienna, Austria), and the 
rms package was used to model restricted cubic splines. 
The Danish Data Protection Agency approved the study 
(record number 2015-57-0002, Aarhus University record 
number 2016-051-000001/432). According to Danish law, 




Of 59,520 adult ICU patients admitted during the study 
period, 51,517 patients were considered eligible for this 
study (Fig. 1). In total, 37,293 (72%) patients had at least 
one lactate level 12 h before until 6 h after ICU admission 
and were included in the final analysis (Additional file 1: 
Table S1). Lactate levels were more often not available at 
the beginning of data capture (e.g., in 2010 or 2011) and 
in patients with a relatively lower risk profile. Lactate lev-
els were more often reported for metformin users than 
nonusers (80% vs. 72%). Three patients were lost to fol-
low-up within 30 days after inclusion.
Median (interquartile range, IQR) age was 68 (56–77) 
years, 57% were male, and 3183 (9%) patients used met-
formin. Four metformin users did not have a diagnosis 
of diabetes mellitus, but these patients had a diagnosis 
of polycystic ovarian syndrome recorded within 10 years 
before ICU admission. The proportion of patients with 
diabetes increased in patients admitted with higher lac-
tate levels (Table 1). The percentage of metformin users 
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Table 1 Patient characteristics stratified by lactate level category
Characteristic Total < 1.4 1.4 to 2.0 2.0 to 3.2 3.2 to 5.0 5.0 to 10.0 ≥ 10
No. of patients 37,293 14,572 8705 6831 3694 2544 947
Age, years 68 [56–77] 68 [57–77] 67 [55–77] 67 [53–77] 68 [55–77] 68 [56–77] 66 [55–74]
Male 21,244 (57) 8010 (55) 4971 (57) 3999 (59) 2125 (58) 1552 (61) 587 (62)
Charlson Comorbidity Index
 0 13,769 (37) 5122 (35) 3311 (38) 2667 (39) 1337 (36) 954 (38) 378 (40)
 1–2 14,005 (38) 5696 (39) 3248 (37) 2468 (36) 1344 (36) 931 (37) 318 (34)
 ≥ 3 9519 (26) 3754 (26) 2146 (25) 1696 (25) 1013 (27) 659 (26) 251 (27)
Preadmission disease
 Diabetes mellitus 7703 (21) 2790 (19) 1787 (21) 1404 (21) 812 (22) 673 (26) 237 (25)
 Myocardial infarction 2630 (7) 1108 (8) 621 (7) 425 (6) 251 (7) 162 (6) 63 (7)
 Congestive heart failure 3520 (9) 1424 (10) 837 (10) 594 (9) 341 (9) 236 (9) 88 (9)
 Peripheral vascular disease 4104 (11) 1648 (11) 998 (11) 681 (10) 400 (11) 278 (11) 99 (10)
 Cerebrovascular disease 5065 (14) 2084 (14) 1138 (13) 876 (13) 511 (14) 333 (13) 123 (13)
 Chronic pulmonary disease 6863 (18) 3011 (21) 1563 (18) 1151 (17) 642 (17) 387 (15) 109 (12)
 Cancer 6735 (18) 2771 (19) 1525 (18) 1238 (18) 683 (18) 401 (16) 117 (12)
 Mild-to-severe liver disease 1531 (4) 384 (3) 315 (4) 292 (4) 218 (6) 217 (9) 105 (11)
Renal function during 1 year before ICU  admissiona
 eGFR, mL/min/1.73 m2 80 [59–95] 80 [58–95] 81 [61–95] 81 [59–96] 80 [59–96] 81 [59–96] 85 [62–99]
 ≥ 60 mL/min/1.73 m2 22,770 (74) 9029 (73) 5399 (76) 4041 (75) 2234 (74) 1506 (74) 561 (77)
 45–60 mL/min/1.73 m2 3773 (12) 1531 (12) 808 (11) 713 (13) 371 (12) 263 (13) 87 (12)
 30–45 mL/min/1.73 m2 2402 (8) 1020 (8) 528 (7) 398 (7) 242 (8) 162 (8) 52 (7)
 < 30 mL/min/1.73 m2 1641 (5) 755 (6) 352 (5) 244 (5) 163 (5) 98 (5) 29 (4)
 Dialysis before ICU  admissionb 344 (1) 139 (1) 85 (1) 52 (1) 43 (1) 19 (1) 6 (1)
Antihyperglycemic therapy
 Metformin 3183 (9) 1047 (7) 758 (9) 596 (9) 353 (10) 300 (12) 129 (14)
 Sulfonylureas 899 (2) 309 (2) 233 (3) 150 (2) 104 (3) 72 (3) 31 (3)
 Insulin 2343 (6) 853 (6) 551 (6) 428 (6) 236 (6) 220 (9) 55 (6)
 Other antihyperglycemic agents 691 (2) 206 (1) 158 (2) 131 (2) 88 (2) 72 (3) 36 (4)
 HbA1c within 4 weeks before ICU admis-
sion,  %c
5.9 [5.5–6.7] 5.9 [5.5–6.5] 6.0 [5.5–6.7] 6.1 [5.5–7.0] 6.1 [5.5–6.9] 6.1 [5.5–7.0] 5.9 [5.5–7.0]
ICU admission  typed
 Medical 17,926 (52) 5864 (43) 4033 (50) 3575 (56) 2188 (63) 1622 (68) 644 (73)
 Emergency surgery 10,683 (31) 4111 (30) 2506 (31) 2041 (32) 1078 (31) 722 (30) 225 (26)
 Elective surgery 6193 (18) 3623 (27) 1576 (19) 738 (12) 187 (5) 56 (2) 13 (1)
 SAPS-II  scoree 40 [30–52] 35 [26–45] 38 [29–49] 41 [31–53] 47 [36–60] 54 [42–67] 62 [50–76]
Primary diagnostic category
 Cardiovascular 8466 (23) 3668 (25) 1931 (22) 1183 (17) 721 (20) 667 (26) 296 (31)
 Respiratory, incl. pneumonia 5244 (14) 2223 (15) 1251 (14) 972 (14) 498 (13) 248 (10) 52 (5)
 Infection or sepsis, excl. pneumonia 3425 (9) 1054 (7) 789 (9) 689 (10) 476 (13) 335 (13) 82 (9)
 Gastrointestinal and liver disease 4215 (11) 1635 (11) 923 (11) 783 (11) 435 (12) 313 (12) 126 (13)
 Neoplasms 3899 (10) 1777 (12) 971 (11) 713 (10) 282 (8) 125 (5) 31 (3)
 Trauma and poisoning 5014 (13) 1887 (13) 1247 (14) 1109 (16) 446 (12) 255 (10) 70 (7)
 Endocrinology 1013 (3) 381 (3) 203 (2) 226 (3) 93 (3) 79 (3) 31 (3)
 Other 6017 (16) 1947 (13) 1390 (16) 1156 (17) 743 (20) 522 (21) 259 (27)
Laboratory values 12 h before until 6 h after ICU admission
 First lactate, mmol/L 1.6 [1.0–3.0] 0.9 [0.7–1.2] 1.7 [1.4–2.0] 2.6 [2.1–3.3] 4.2 [3.4–5.5] 7.4 [5.6–9.6] 14.0 [11.4–17.0]
 Mean lactate, mmol/L 1.6 [1.1–2.8] 0.9 [0.8–1.1] 1.6 [1.5–1.8] 2.5 [2.3–2.8] 3.9 [3.5–4.4] 6.6 [5.7–7.9] 13.0 [11.3–15.8]
 Maximum lactate, mmol/L 2.1 [1.3–3.7] 1.1 [0.9–1.4] 2.0 [1.8–2.5] 3.2 [2.7–4.0] 5.1 [4.3–6.4] 8.8 [7.1–10.8] 15.3 [13.0–18.9]
 No. of lactate measurements 4 [2–6] 3 [2–5] 4 [2–6] 4 [2–6] 4 [2–6] 4 [2–7] 3 [1–7]
 Mean glucose, mmol/Lf 8.1 [6.7–10.1] 7.3 [6.3–8.6] 8.3 [7.0–9.9] 8.8 [7.1–10.9] 9.4 [7.4–12.1] 10.0 [7.4–13.6] 9.8 [6.8–14.1]
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also increased in patients admitted  with higher lactate 
levels, whereas this trend was not observed for insulin, 
sulfonylureas, or other glucose-lowering drugs. Patients 
admitted with high lactate levels more often had a history 
of mild-to-severe liver disease. Compared with nonus-
ers, metformin users more often had a history of chronic 
pulmonary and cardiovascular disease (Additional file 1: 
Table S3). The median (IQR) preadmission eGFR was 80 
(59–95) mL/min/1.73 m2, which was similar for patients 
when categorised according to either lactate level or met-
formin use. However, a larger proportion of nonusers 
had severe chronic kidney disease and required dialysis 
before ICU admission. The SAPS-II score increased when 
admitted with higher lactate levels, as was the number of 
patients requiring mechanical ventilation, inotropes or 
vasopressors, and RRT. While the SAPS-II score was sim-
ilar for metformin users and nonusers, metformin users 
more often were treated with mechanical ventilation, 
inotropes or vasopressors, and RRT.
Lactate level and outcome
In 12 h before until 6 h after ICU admission, lactate was 
measured a median (IQR) 4 (2–6) times per patient. 
The number of measurements was not different for 
patients admitted with increased lactate levels and 
did not differ between metformin users and nonusers 
Blood lactate level category based on quintiles and clinically relevant boundaries in mmol/L. Data are expressed as n (%) or median [IQR]
a Data missing for 6707 (18%) patients
b As per Danish regulation, frequencies smaller than five patients not being zero are not reported
c Data missing for 31,373 (84%) patients
d Data missing for 2491 (7%) patients
e Data missing for 25,932 (70%) patients
f Data missing for 807 (2%) patients
g Data missing for 2885 (8%) patients
Table 1 (continued)
Characteristic Total < 1.4 1.4 to 2.0 2.0 to 3.2 3.2 to 5.0 5.0 to 10.0 ≥ 10
ICU treatment
 Mechanical ventilation 15,594 (42) 5377 (37) 3441 (40) 2839 (42) 1838 (50) 1466 (58) 633 (67)
 Inotropes or vasopressors 13,081 (35) 3712 (25) 2854 (33) 2641 (39) 1811 (49) 1461 (57) 602 (64)
 Renal replacement therapy 1919 (5) 440 (3) 316 (4) 351 (5) 291 (8) 331 (13) 190 (20)
 ICU length of stay,  daysg 1.1 [0.7–2.8] 1.0 [0.7–2.1] 1.0 [0.7––2.8] 1.2 [0.6–3.3] 1.5 [0.7–4.0] 1.5 [0.6–4.3] 1.0 [0.4–3.3]
 Hospital length of stay, days 10 [5–20] 10 [6–20] 11 [6–21] 10 [5–21] 10 [4–21] 9 [3–21] 5 [1–15]
51,517 Pa nts eligible
59,520 Adults admi ed to ICUs
in Northern or Central Denmark 
Region between January 2010
and August 2017 8003 Pa ents excluded
7075 Not living 1 year before
ICU admission within region
883 Died within 6 hours of ICU 
admission
45 Follow-up data unavailable
14,224 Pa nts without 
available lactate 
measurement
34,110 Me ormin 
nonusers
3183 Me ormin 
users
37,293 Pa nts with 
available lactate 
measurement
Fig. 1 Flowchart of included patients
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(Table  1 and Additional file  1: Table  S3). The median 
(IQR) lactate level was 1.8 (1.2–3.2) mmol/L for met-
formin users and 1.6 (1.0–2.7) mmol/L for metformin 
nonusers, resulting in a mean (95% CI) difference of 
0.2 (0.2 to 0.3) mmol/L (Additional file  1: Fig. S2, S3). 
Compared with nonusers, metformin users more often 
had a maximum lactate level ≥ 2 mmol/L (43% vs. 38%, 
Additional file 1: Fig. S3). In total, 7768 (21%) patients 
died during 30 days of follow-up.
Lactate levels were strongly associated with mortal-
ity (Fig.  2). Over the whole range of lactate levels, met-
formin users had a lower mortality rate than metformin 
nonusers. Therefore, the relation of lactate with mortal-
ity was shifted rightwards for metformin users (Figs.  2, 
3). Compared with metformin users with a lactate 
level < 1.4 mmol/L, nonusers with a lactate < 1.4 mmol/L 
had essentially the same mortality risk (Table  2). Com-
pared to metformin nonusers with a lactate < 1.4 mmol/L, 






























Fig. 2 Association of lactate level with estimated 30-day mortality for metformin users and nonusers. Data were computed using the one minus 
the Kaplan–Meier survival estimate. Restricted cubic splines were constructed with four evenly spaced knots based on quantiles. A multiply 
imputed dataset was used for this analysis. The grey area represents the 95% confidence interval
Page 7 of 11Posma et al. Ann. Intensive Care           (2020) 10:36  
2.0 mmol/L had a higher mortality risk (HR 1.45, 95% CI 
1.35–1.55), while this was less pronounced in metformin 
users with a lactate between 1.4 and 2.0  mmol/L (HR 
1.15, 95% CI 0.94–1.39). The risk further increased in 
patients admitted with higher lactate categories for both 
metformin users and nonusers. However, this increase in 
risk was less pronounced for metformin users than non-
users, which was confirmed by interaction of which the 
magnitude increased for patients presenting with higher 
lactate levels (Table 2).
Sensitivity analyses
Our observations did not alter materially when we: (1) 
restricted our analysis to complete cases; (2) adjusted 
for the number of lactate measurements; (3) applied 
a logistic regression model to determine the rela-
tion of lactate with outcome, or (4) used first or maxi-
mum lactate level as exposure (Additional file  1: Figs. 
S4–S6 and Tables S4–S6). Although metformin users 
had baseline characteristics and mortality rate differ-
ent from patients with diabetes not using metformin 
(Additional file  1: Tables S7, S8 and Fig. S2), the rela-
tion of lactate with mortality was shifted rightwards for 
metformin users in this subgroup as well (Additional 
file 1: Table S9, Fig. S7). Among 6193 patients undergo-
ing elective surgery, 672 (11%) patients used metformin 
(Additional file  1: Table  S10). Lactate levels were also 
associated with mortality in this small subgroup, but 
we did not observe a clear effect modification by met-
formin use (Additional file  1: Table  S11 and Fig. S8). 
When stratified by preadmission renal function (Addi-
tional file 1: Table S12–S14, Fig. S2), effect modification 
by metformin use was more pronounced in patients 
with an eGFR smaller than 60  mL/min/1.73  m2 when 
categorising lactate levels (Additional file 1: Table S15), 
but we could not fully substantiate this finding when 
Fig. 3 Association of lactate level with adjusted hazard ratio for 30-day mortality among metformin users and nonusers in the total cohort. The 
panel on the right is a zoomed-in version of the left panel and corresponds with the range of lactate levels that includes the largest proportion of 
patients. Data were fit by a multivariable-adjusted Cox regression model based on restricted cubic splines constructed with four evenly spaced 
knots. A multiply imputed dataset was used for this analysis. The grey area represents the 95% confidence interval
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modelling lactate as a continuous variable (Additional 
file 1: Fig. S9).
Discussion
In this registry-based cohort study of more than 37,000 
patients admitted to ICUs in northern Denmark, we con-
firmed a strong association of early lactate elevation with 
adverse outcomes. Over the whole range of lactate lev-
els, metformin users had lower mortality than metformin 
nonusers. The association of lactate with mortality was 
thus shifted rightwards for metformin users, meaning 
that metformin users have a lower mortality rate when 
admitted with similar lactate levels as metformin nonus-
ers. Therefore, the prognostic value of lactate was modi-
fied by metformin use in our study.
The most straightforward explanation of our results 
is that lactate metabolism is affected by metformin due 
to its prime mode of action, inhibition of gluconeogen-
esis (i.e., synthesis of glucose from circulating lactate) 
[5, 7, 11]. A related explanation could be that metformin 
users are more susceptible to generate lactate because 
of systemic but mild suppression of mitochondria [8, 9, 
13], although this has hitherto only been demonstrated 
in cases with toxic metformin levels [12]. Metformin 
users generally have more comorbidities than the total 
population, which might affect the decision to admit 
these patients at an earlier stage of critical illness to the 
ICU. For that reason, selection bias might contribute 
to the fact that metformin users have a more favour-
able outcome. However, the same rightward shift of the 
association of lactate with mortality was observed when 
restricting to patients with diabetes, among whom met-
formin users had a lower risk profile compared to met-
formin nonusers with diabetes. Likewise, metformin 
users may carry a lower mortality risk compared with 
nonusers when admitted to an ICU, as observed previ-
ously in a Danish nationwide registry-based study and 
by other observational studies [27, 47, 48]. Preclinical 
data indicate that metformin is associated with reduced 
inflammation, thrombosis, and apoptosis [49]. However, 
randomiaed controlled trials do not provide evidence 
that metformin affected the mortality rate of critically ill 
patients, although they are underpowered for this out-
come [50–52]. Larger trials are warranted to evaluate fur-
ther the use of metformin as adjuvant or even protective 
agent in intensive care.
Importantly, by including more than 37,000 critically 
ill patients from 10 ICUs, our study is one of the larg-
est studies to investigate the association of circulating 
lactate levels with outcome. Moreover, this is the larg-
est study investigating the impact of metformin on this 
relation. Our hypothesis [13] was sparked by a previous 
study including 162 patients admitted to an ICU with 
overt hyperlactataemia and septic shock [15]. In that 
study, metformin users had a better prognosis compared 
with nonusers, but effect modification by metformin 
Table 2 Thirty-day mortality, hazard ratios, and  the  relative excess risk due to  interaction by  lactate category 
for metformin nonusers and users
Hazard ratio (HR) with 95% confidence interval (CI) was computed using Cox proportional regression analysis based on a multiply imputed datasets
a Adjusted for age, gender, last HbA1c measurement within 4 weeks before ICU admission, mean of all creatinine measurements 1 year before ICU admission, and 
previous diagnosis of myocardial infarction, congestive heart failure, peripheral artery disease, cerebrovascular disease, dementia, connective tissue disease, peptic 
ulcer disease, chronic pulmonary disease, mild-to-severe liver disease, any tumour, metastatic solid tumour, leukaemia, and lymphoma, respectively, 10 years before 
ICU admission. Codes used for each variable are stated in Additional file 1: Appendix S1
b Relative excess risk due to interaction (RERI) quantifies interaction on an additive scale, which approaches zero in the absence of interaction
Lactate 
(mmol/L)













< 1.4 1784/13,525 (13%) 136/1047 (13%) Reference 0.98 (0.82 to 1.16) Reference 0.95 (0.80 to 1.14)
1.4 to 2.0 1400/7947 (18%) 114/758 (15%) 1.37 (1.28 to 
1.47)
1.15 (0.95 to 1.39) 1.45 (1.35 to 
1.55)
1.15 (0.94 to 1.39) − 0.25 (− 0.54 to 
0.03)
2.0 to 3.2 1422/6235 (23%) 116/596 (19%) 1.84 (1.72 to 
1.97)
1.53 (1.27 to 1.85) 2.00 (1.87 to 
2.15)
1.53 (1.26 to 1.86) − 0.42 (− 0.77 to 
− 0.07)
3.2 to 5.0 1082/3341 (32%) 84/353 (24%) 2.80 (2.60 to 
3.02)
1.90 (1.53 to 2.36) 2.99 (2.77 to 
3.22)
1.86 (1.49 to 2.33) − 1.08 (− 1.55 to 
− 0.60)
5.0 to 10.0 964/2244 (43%) 105/300 (35%) 4.17 (3.86 to 
4.51)
3.16 (2.59 to 3.84) 4.58 (4.24 to 
4.96)
3.10 (2.54 to 3.80) − 1.43 (− 2.13 to 
− 0.74)
≥ 10.0 498/818 (61%) 63/129 (49%) 7.60 (6.88 to 
8.39)
5.20 (4.04 to 6.69) 9.24 (8.35 to 
10.21)
5.51 (4.27 to 7.12) − 3.68 (− 5.30 to 
− 2.05)
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use was not assessed. Consistent with our results, oth-
ers report that the optimal lactate level on the receiver 
operating characteristics curve was higher in critically ill 
metformin users than nonusers [14]. In a single-centre 
study including 1947 patients with suspected sepsis at the 
emergency department, metformin use also modified the 
association of lactate with outcome [16]. Other studies 
did not observe differences in lactate level between met-
formin users and nonusers [18, 19–22]. Of note, most of 
these studies included patients with a relatively low-risk 
profile, such as after cardiovascular surgery [20–22] or 
patients not admitted to an ICU [19].
As the presentation with high lactate levels is associ-
ated with an unfavourable outcome, an important practi-
cal clinical consequence is that metformin users do not 
carry the same risk as metformin nonusers when admit-
ted with similar lactate levels. For example, the mortality 
rate in patients with a lactate of 5–10 mmol/L was 43% 
in metformin nonusers, whereas metformin users with 
this lactate category had a mortality rate of 35%. There-
fore, clinicians could be more lenient regarding lactate 
as a prognostic marker for metformin users compared 
to nonusers with a similar lactate level. Even for lactate 
levels within the reference range, a mild increase in lac-
tate was associated with a higher mortality risk for met-
formin nonusers. Additionally, patients with septic shock 
can be identified according to the Sepsis-3 definition by a 
lactate ≥ 2 mmol/L [42]. In our general ICU population, 
metformin users crossed this threshold level more often 
than nonusers. Although not investigated in the current 
study, metformin users might fulfil these criteria at an 
earlier stage of disease severity than nonusers with septic 
shock.
Metformin has been repeatedly, although infrequently, 
associated with lactic acidosis [11]. Currently, the inci-
dence of metformin-associated lactic acidosis remains 
unclear but has been reported as 3 to 10 cases per 100,000 
person-years [46]. We found that the magnitude of effect 
modification by metformin was more pronounced when 
lactate levels increased. This observation is not surprising 
since increasing metformin levels increasingly affect lac-
tate metabolism, as attested in extremo in patients with 
metformin-associated lactic acidosis [53]. As expected 
from its mitochondrial inhibitory effect [5, 8, 9], both 
increased lactate generation and impaired lactate uti-
lisation are explanations for the relatively higher lactate 
levels in metformin users than nonusers within the same 
mortality category. Since the major mode of metformin 
elimination is the excretion of unchanged drug in urine, 
patients with reduced kidney function are more prone 
to develop toxic metformin levels [11, 46]. In line with 
our expectations and previous studies [45, 54], effect 
modification by metformin was more pronounced in 
patients with chronic kidney disease.
The strengths of our study included its large sample 
size, high data validity, and practically no loss to fol-
low-up. Furthermore, all data were prospectively col-
lected and independent of the current study, thereby 
limiting the risk of information bias. The findings from 
the present study should be considered in light of sev-
eral limitations. Lactate levels were not measured or 
reported in 28% of eligible patients. Although some can 
be explained by not all hospitals reporting lab data at 
the beginning of the study period, lactate levels were 
more often measured in metformin users compared 
with nonusers, which might have resulted in selection 
bias. Nearly all patients using metformin had diabetes, 
while most metformin nonusers did not, introducing 
potential confounding by indication [55]. However, our 
results were not altered when restricting our dataset 
to patients with diabetes exclusively. Moreover, diabe-
tes has been associated with attenuation of lactate lev-
els after cardiac surgery [56]. Having diabetes would, 
therefore, counteract any effects of metformin on lac-
tate, thus biasing our results towards no difference and 
therefore not changing our conclusions. Still, our non-
randomised design may have led to confounding by fac-
tors related to the choice of metformin as treatment. 
To address this possibility, we extensively adjusted 
our results for a wide range of potential confounders, 
which did not materially alter our results. Because the 
exposure in this study was a relatively short time win-
dow, static rather than dynamic indices of lactataemia 
were used to predict mortality. Of dynamic indices, 
time-weighted average lactate levels are shown to have 
the strongest association with both ICU and hospital 
mortality [57], which we approximated by calculating 
the mean of all lactate levels around ICU admission. 
Given the current inclusion criteria, we were not able 
to assess lactate kinetics adequately, which is a limita-
tion of our study.
Conclusions
In this large cohort of critically ill patients admitted to 
ICUs in northern Denmark, early lactate levels were 
strongly associated with mortality. Irrespective of the 
degree of hyperlactataemia, similar lactate levels were 
associated with a lower mortality rate in metformin 
users compared to metformin nonusers. Our findings 
suggest that metformin interacts with lactate metabo-
lism in critically ill patients. Therefore, lactate levels 
around ICU admission should be interpreted according 
to metformin use.
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